Celcuity Appoints Eldon Mayer as Chief Commercial Officer

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology.

“Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company’s first drug. His significant commercial experience at multiple biopharma companies, large and small, launching a variety of different drugs in different markets and scaling them, make him the ideal candidate to lead the potential commercial launch of Celcuity’s inaugural product, gedatolisib,” said Brian Sullivan, Celcuity’s Chief Executive Officer and co-founder. “We believe gedatolisib has a unique opportunity to become a transformational therapy in multiple tumor types, and Eldon has the right background to help gedatolisib realize this potential.”

Prior to joining Celcuity, Mr. Mayer served as Executive Vice President and Chief Commercial Officer at Eiger Biopharmaceuticals where he led the commercial planning and execution of several pipeline assets including international partnerships as well as the global launch of Zokinvy for progeria and progeroid laminopathies. Prior to Eiger, he was Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals where he built and led the commercial organization and launched Tavalisse (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia. Mr. Mayer has also served as Senior Vice President of Commercial Operations at Questcor Pharmaceuticals where he built a large commercial team that generated over $1 billion in annual sales of Acthar Gel (repository corticotropin injection). Questcor was acquired by Mallinckrodt for $5.6 billion in 2014. Earlier in his career, he held positions of increasing responsibilities at companies including Schering-Plough, ALZA, Chiron, and Connetics, in functional areas including strategic planning, marketing, sales, market research and analytics, operations and finance.